Research & Development

Investigational Therapeutic for
Episodic Cardiovascular Conditions

Etripamil Clinical Pipeline

AREA OF FOCUS PRECLINICAL PHASE I PHASE II PHASE III PHASE

Rapid conversion to sinus rhythm

PHASE III

Temporary control of rapid ventricular rate

RESEARCH

Acute relief of angina symptoms

RESEARCH

Our lead pipeline candidate etripamil is a proprietary chemical entity that was conceived, discovered and optimized by Milestone.

Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the acute treatment of patients with PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

Etripamil is not currently approved for the treatment of PSVT or for any other indication anywhere in the world.